Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Randomized, Active-controlled, Parallel Group, Pivotal Study to Investigate the Efficacy, Safety and Tolerability, and Pharmacokinetics of Murepavadin Combined With One Anti-pseudomonal Antibiotic Versus Two Anti-pseudomonal Antibiotics in Adult Subjects With Ventilator-associated Bacterial Pneumonia Suspected or Confirmed to be Due to Pseudomonas Aeruginosa
Conditions
Interventions
Murepavadin
Two anti-pseudomonal antibiotics
Locations
61
United States
Research site
Chicago, Illinois, United States
Research site
Springfield, Missouri, United States
Research site
Greensboro, North Carolina, United States
Research Site 1
Belo Horizonte, Brazil
Research Site 2
Belo Horizonte, Brazil
Research Site
Itaquaquecetuba, Brazil
Start Date
March 23, 2018
Primary Completion Date
July 17, 2019
Completion Date
July 17, 2019
Last Updated
August 28, 2019
NCT07409727
NCT07186933
NCT06169514
NCT06092008
NCT07298889
NCT06750536
Lead Sponsor
Polyphor Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions